MedTrace Logo

A Retrospective Analysis of Cerefolin NAC® in Cognitively Impaired Patients

NCT01594541 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 700

Last updated 2014-03-24

No results posted yet for this study

Summary

This retrospective analysis of de-identified data from 700 charts of consecutive patients from this patient population is to investigate the prevalence of hyperhomocysteinemia and associated metabolic abnormalities in this naturalistic grouping of patients with various stages of cognitive loss and diagnosed with various types of dementia.

Conditions

Sponsors & Collaborators

  • Clionsky Neuro Systems Inc.

    collaborator INDUSTRY

  • Pamlab, Inc.

    lead INDUSTRY

Principal Investigators

  • Emily Clionsky, MD · Clionsky Neuro Systems Inc.

Eligibility

Min Age
55 Years
Max Age
89 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-01-31
Primary Completion
2013-08-31
Completion
2014-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01594541 on ClinicalTrials.gov